Business Context and Reporting Period
This Form 6-K filing by Ambev S.A. reports on a Board of Directors meeting held on May 15, 2019, in Buenos Aires, Argentina. The document serves as a disclosure of corporate governance resolutions rather than a financial performance report for the period ending June 30, 2019.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only quantitative data disclosed relates to capital structure and authorized derivative exposure:
- Outstanding Shares: 343,742,744
- Treasury Shares: 369,550
- Authorized Equity Swap Exposure: Up to 80 million common shares (or ADRs) with a limit value of up to R$1.5 billion.
- Total Potential Exposure: Including unsettled agreements from prior approvals, total exposure may reach up to 210,784,853 common shares.
Material Changes
No material changes to financial performance or operational results are reported. The primary material change is the Board's approval of:
- Updates to the "Manual on Disclosure and Use of Information and Securities Trading Policy."
- Authorization for new equity swap agreements to hedge share-based compensation programs.
Guidance, Outlook, and Risks
Management Commentary: The Board authorized equity swaps to neutralize the financial impact of stock price oscillations on share-based payment programs. The company intends to receive price variations on its shares/ADRs while paying CDI or LIBOR plus a fee. These agreements are financially settled and will not involve the physical purchase or disposal of shares.
Risks and Contingencies:
- Counterparty Risk: Agreements may be terminated by financial institutions if the share price depreciates by 50% or more.
- Settlement Terms: The maximum term for settlement is 18 months (until November 15, 2020).
- Financial Impact: The Board confirmed the company's current financial situation is compatible with these operations and that they will not affect obligations to creditors or mandatory dividend payments.
Investor Verification Checklist
- Verify the current market price of Ambev shares and ADRs to assess the potential value of the R$1.5 billion exposure limit.
- Review the updated "Manual on Disclosure and Use of Information and Securities Trading Policy" for changes in corporate governance standards.
- Monitor future filings for the actual execution of the equity swaps and the identity of the financial institution counterparties.
- Confirm that the total exposure (including prior approvals) remains within the regulatory limits set by CVM Ruling No. 567/15.